Temporal bone metastasis is hematogenous spread from a primary malignancy elsewhere in the body to the temporal bone. The most common primary sources are breast (38%), lung (12%), kidney (12%), prostate (7%), and melanoma (5%) cancers. Temporal bone metastases constitute 4-7% of all temporal bone malignancies, but autopsy series detect temporal bone involvement in 20-22% of cancer patients — most are clinically silent. The most common sites of involvement are the petrous apex (rich bone marrow for hematogenous spread) and mastoid process. Facial nerve paralysis can be the first symptom of temporal bone metastasis and occurs in 30-40% of cases — indicating advanced disease. Hearing loss (conductive or sensorineural), otorrhea, vertigo, and cranial nerve palsies are other clinical findings. Diagnosis is usually established by combining CT and MRI findings with known primary malignancy history.
Age Range
40-80
Peak Age
60
Gender
Equal
Prevalence
Uncommon
Temporal bone metastases form through three pathways: (1) Hematogenous spread — most common mechanism, the rich vascular network in petrous apex and mastoid bone marrow (Batson venous plexus) allows tumor cell seeding; (2) Direct extension — from nasopharynx, parotid, or skull base tumors by contiguity; (3) Leptomeningeal spread — reaches internal auditory canal and inner ear via CSF pathways. In hematogenous spread, tumor cells settle in bone marrow and initiate lytic bone destruction through osteoclast activation (RANKL pathway) — appearing as irregularly marginated lytic lesion on CT. Osteoblastic (sclerotic) component may also be seen in prostate and breast metastases. On MRI, tumor infiltration causes loss of normal fatty marrow T1 hyperintense signal (T1 hypointensity) and shows variable signal on T2 — this bone marrow replacement is the most sensitive MRI finding of metastasis. Facial nerve involvement occurs through perineural invasion and/or Fallopian canal bone destruction.
Triad of irregularly marginated destructive lytic lesion in the temporal bone with facial nerve paralysis in a patient with known primary malignancy history — nearly diagnostic for temporal bone metastasis. This triad enables diagnosis through combination of clinical and imaging findings.
Irregularly marginated destructive lytic bone lesion. Cortical break and trabecular bone destruction are prominent. Surrounding reactive sclerosis minimal or absent. Soft tissue component may extend through bone defect.
Report Sentence
An irregularly marginated destructive lytic lesion measuring ___ x ___ mm in the temporal bone is identified, consistent with metastatic disease; clinical correlation with known primary malignancy history is recommended.
Loss of normal fatty marrow hyperintense signal on T1-weighted images — hypointense signal due to tumor infiltration. This bone marrow replacement is the most sensitive MRI finding of metastasis and can be detected before CT.
Report Sentence
Loss of normal fatty marrow signal and hypointense infiltration in the temporal bone marrow is observed on T1-weighted images, consistent with bone marrow metastasis.
Pathological enhancement and/or nodular thickening of intratemporal facial nerve segments on post-contrast T1. Fallopian canal bone destruction may accompany. Indicates perineural tumor spread.
Report Sentence
Pathological enhancement of the ___ segment of the facial nerve is observed on contrast-enhanced series, suggesting perineural tumor spread.
Bone erosion of the Fallopian (facial nerve) canal — destruction of cortical canal wall. Shows structural cause of facial nerve paralysis. Critical finding for surgical planning.
Report Sentence
Bone erosion of the Fallopian canal at the ___ segment is observed, suggesting metastatic tumor invasion; clinical correlation with facial nerve paralysis is recommended.
Diffusion restriction on DWI — reflects dense tumor cellularity. ADC values are low. Distinguished from other temporal bone lesions showing diffusion restriction like cholesteatoma in clinical context.
Report Sentence
Diffusion restriction in the lesion is observed on DWI (ADC: ___ x 10-3 mm2/s), consistent with dense tumor cellularity.
Criteria
Blood-borne spread. Most common mechanism. Petrous apex and mastoid involvement typical.
Distinct Features
Accompanying multiple bone metastases common. Isolated temporal bone metastasis rare. Breast and prostate most common primary sources.
Criteria
Direct invasion from adjacent structures. Nasopharynx, parotid, EAC SCC.
Distinct Features
Lesion shows continuity from adjacent structure. Primary tumor usually identifiable. Periosteal reaction and peritumoral edema may be prominent.
Criteria
Spread via CSF pathways. Internal auditory canal and inner ear involvement. Rare mechanism.
Distinct Features
Internal auditory canal enhancement. Cochlear and vestibular nerve involvement. Sensorineural hearing loss predominant. Primary usually brain tumor or leukemia/lymphoma.
Distinguishing Feature
LCH shows sharply marginated 'punched-out' lytic lesion — no sclerotic rim; metastasis has more irregular margins. LCH occurs in children, metastasis in older adults.
Distinguishing Feature
CT is normal in Bell's palsy with no bone destruction; facial nerve enhancement on MRI is linear and smooth. Metastasis shows bone destruction and nodular nerve thickening.
Distinguishing Feature
Fibrous dysplasia is an expansile ground-glass density lesion — intact cortex; metastasis is a destructive lytic lesion — cortical break. Age group differs — FD in young, metastasis in elderly.
Urgency
urgentManagement
medicalBiopsy
Not NeededFollow-up
3-monthTemporal bone metastasis indicates advanced systemic disease and prognosis is generally poor (median survival 6-18 months). Biopsy is usually unnecessary — known primary malignancy and characteristic imaging findings establish diagnosis. Treatment is palliative: radiotherapy for pain control and tumor reduction, surgery in limited cases. Facial nerve paralysis may respond well to radiotherapy. Whole-body staging (PET-CT) should screen for other metastatic sites.
Temporal bone metastasis indicates advanced systemic disease. Facial nerve paralysis significantly affects quality of life. Radiotherapy is the first choice for palliative treatment. Surgery may be considered in limited cases.